文献速递淋巴瘤

儿童间变性大细胞淋巴瘤的进展与更新

Advances and updates in pediatric anaplastic large cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

儿童间变性大细胞淋巴瘤多为ALK阳性,强化多药化疗后治疗失败率仍达25%至30%。靶向治疗(ALK抑制剂、维布妥昔单抗)在复发难治中显示显著活性,MDD/MRD分子检测可改善预后分层。免疫治疗提供更多选择,将靶向治疗与MDD/MRD评估纳入临床试验可能显著改善儿童和青少年患者结局。

要点

  • 儿童ALCL多为ALK阳性,强化多药化疗后治疗失败率仍为25%至30%。
  • ALK抑制剂和维布妥昔单抗在复发难治ALCL中显示显著活性。
  • MDD/MRD分子检测可改善预后分层,将靶向治疗与MDD/MRD评估纳入临床试验可能显著改善结局。

核心结论

  • 将靶向治疗和MDD/MRD评估纳入临床试验可能显著改善儿童和青少年ALCL患者的结局。
  • 复发难治患者中靶向治疗增加了治疗选择,但仍需更多工作确定最佳方案、疗程及造血干细胞移植的必要性。

研究设计与样本

  • 综述,总结儿童间变性大细胞淋巴瘤的进展与更新。

主要发现

  • 儿童ALCL多数为ALK阳性,尽管采用强化多药化疗方案,治疗失败率仍为25%至30%。
  • ALK抑制剂和抗CD30抗体药物偶联物维布妥昔单抗在复发和难治情况下显示出显著活性。
  • MDD和MRD的分子检测可改善预后分层。
  • 免疫治疗如检查点抑制剂或嵌合抗原受体T细胞治疗提供额外治疗选择。

临床怎么用

  • 将靶向治疗和MDD/MRD评估纳入临床试验可能显著改善儿童和青少年ALCL患者的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic large cell lymphoma (ALCL) is a rare form of mature T-cell non-Hodgkin lymphoma. In pediatric patients, most cases are anaplastic lymphoma kinase (ALK) positive. Despite intensive multiagent chemotherapy regimens, treatment failure rates remain at 25% to 30%. Recent advancements in targeted therapies, notably ALK inhibitors and the anti-CD30 antibody-drug conjugate brentuximab vedotin have demonstrated substantial activity in relapsed and refractory settings. Molecular detection of minimal disseminated disease (MDD) and minimal residual disease (MRD) offers improved prognostic stratification. For patients with relapsed or refractory disease, targeted therapies have increased treatment options, but more work needs to be done to define optimal treatment regimens, duration, and need for hematopoietic stem cell transplantation in this group. Immune therapies such as checkpoint inhibitors or chimeric antigen receptor T-cell therapy provide additional therapeutic options. Incorporating targeted therapies and MDD/MRD assessments into clinical trials could significantly improve outcomes for pediatric and adolescent patients with ALCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Marks LJ, Lowe E, Kamdar K, et al. Advances and updates in pediatric anaplastic large cell lymphoma. Blood Adv. 2025. PMID: 40690755. doi:10.1182/bloodadvances.2025015935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。